Literature DB >> 22057704

Identification of false-positive QuantiFERON-TB Gold In-Tube assays by repeat testing in HIV-infected patients at low risk for tuberculosis.

Jacob Gray1, Randall Reves, Steven Johnson, Robert Belknap.   

Abstract

The QuantiFERON-TB Gold In-Tube assay (QFT) is increasingly being used for latent tuberculosis screening in patients infected with human immunodeficiency virus (HIV) in the United States. This is a retrospective analysis of repeating positive QFT assays as a strategy to identify false-positive results in HIV-infected patients at low risk for tuberculosis.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22057704     DOI： 10.1093/cid/cir792

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  10 in total

1.  Should all patients undergoing treatment with biologic agents be screened annually for latent tuberculosis infection with an interferon gamma release assay?

Authors:  M G Johnson; R W Bialas; R P Hall; J E Stout
Journal:  J Dermatolog Treat       Date:  2015-12-10       Impact factor: 3.359

2.  Evaluating latent tuberculosis infection diagnostics using latent class analysis.

Authors:  Jason E Stout; Yanjue Wu; Christine S Ho; April C Pettit; Pei-Jean Feng; Dolly J Katz; Smita Ghosh; Thara Venkatappa; Ruiyan Luo
Journal:  Thorax       Date:  2018-07-07       Impact factor: 9.139

3.  Test variability of the QuantiFERON-TB gold in-tube assay in clinical practice.

Authors:  John Z Metcalfe; Adithya Cattamanchi; Charles E McCulloch; Justin D Lew; Ngan P Ha; Edward A Graviss
Journal:  Am J Respir Crit Care Med       Date:  2012-10-26       Impact factor: 21.405

4.  Poor agreement between interferon-gamma release assays and the tuberculin skin test among HIV-infected individuals in the country of Georgia.

Authors:  Nikoloz Chkhartishvili; Russell R Kempker; Natia Dvali; Lela Abashidze; Lali Sharavdze; Pati Gabunia; Henry M Blumberg; Carlos Del Rio; Tengiz Tsertsvadze
Journal:  BMC Infect Dis       Date:  2013-11-01       Impact factor: 3.090

5.  HIV patients with latent tuberculosis living in a low-endemic country do not develop active disease during a 2 year follow-up; a Norwegian prospective multicenter study.

Authors:  Nadine Durema Pullar; Harald Steinum; Johan Nikolai Bruun; Anne Ma Dyrhol-Riise
Journal:  BMC Infect Dis       Date:  2014-12-17       Impact factor: 3.090

6.  Highly Multiplexed Proteomic Analysis of Quantiferon Supernatants To Identify Biomarkers of Latent Tuberculosis Infection.

Authors:  Mary Ann De Groote; Michael Higgins; Thomas Hraha; Kirsten Wall; Michael L Wilson; David G Sterling; Nebojsa Janjic; Randall Reves; Urs A Ochsner; Robert Belknap
Journal:  J Clin Microbiol       Date:  2016-11-16       Impact factor: 5.948

Review 7.  Intraocular manifestations of mycobacterium tuberculosis: A review of the literature.

Authors:  Lauren A Dalvin; Wendy M Smith
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2017-02-17

Review 8.  Orbital and external ocular manifestations of Mycobacterium tuberculosis: A review of the literature.

Authors:  Lauren A Dalvin; Wendy M Smith
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2015-11-27

9.  Cytokine and Chemokine mRNA Expressions after Mycobacterium tuberculosis-Specific Antigen Stimulation in Whole Blood from Hemodialysis Patients with Latent Tuberculosis Infection.

Authors:  Ji Young Park; Sung-Bae Park; Heechul Park; Jungho Kim; Ye Na Kim; Sunghyun Kim
Journal:  Diagnostics (Basel)       Date:  2021-03-26

10.  The Clinical Usefulness of Tuberculin Skin Test versus Interferon-Gamma Release Assays for Diagnosis of Latent Tuberculosis in HIV Patients: A Meta-Analysis.

Authors:  Erfan Ayubi; Amin Doosti-Irani; Ali Sanjari Moghaddam; Mohadeseh Sani; Milad Nazarzadeh; Ehsan Mostafavi
Journal:  PLoS One       Date:  2016-09-13       Impact factor: 3.240
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.